Keymed Biosciences Signs Licensing Deal for Kangyueda in 18 Markets

MT Newswires09-03 09:42

Keymed Biosciences (HKG:2162) has signed a licensing agreement with Singapore-based Aeira to market and sell Kangyueda in 18 markets across Central and Southeast Asia, according to a Wednesday bourse filing.

Kangyueda is approved to treat moderate-to-severe atopic dermatitis in adults, chronic rhinosinusitis with nasal polyposis and seasonal allergic rhinitis, the filing said.

Under the deal, Keymed will receive an upfront payment, milestone payments upon hitting certain targets and royalties in the high-double-digit percentage range based on regional sales.

Aeira will be responsible for regulatory filings and the commercialization of Kangyueda in markets including Singapore, Malaysia, the Philippines, Thailand, Kazakhstan and Uzbekistan, as well as Hong Kong and Macau.

Keymed will oversee the production and timely supply of Kangyueda to Aeira.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2664582856?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-03 09:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2664582856","market":"hk","top_or_hot":-1,"title":"Keymed Biosciences Signs Licensing Deal for Kangyueda in 18 Markets","media":"MT Newswires","content":"<html><body><p> Keymed Biosciences (HKG:2162) has signed a licensing agreement with Singapore-based Aeira to market and sell Kangyueda in 18 markets across Central and Southeast Asia, according to a Wednesday bourse filing.</p><p>Kangyueda is approved to treat moderate-to-severe atopic dermatitis in adults, chronic rhinosinusitis with nasal polyposis and seasonal allergic rhinitis, the filing said.</p><p>Under the deal, Keymed will receive an upfront payment, milestone payments upon hitting certain targets and royalties in the high-double-digit percentage range based on regional sales.</p><p>Aeira will be responsible for regulatory filings and the commercialization of Kangyueda in markets including Singapore, Malaysia, the Philippines, Thailand, Kazakhstan and Uzbekistan, as well as Hong Kong and Macau.</p><p>Keymed will oversee the production and timely supply of Kangyueda to Aeira.</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Keymed Biosciences Signs Licensing Deal for Kangyueda in 18 Markets</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKeymed Biosciences Signs Licensing Deal for Kangyueda in 18 Markets\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1060499803\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires </p>\n<p class=\"h-time\">2026-09-03 09:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Keymed Biosciences (HKG:2162) has signed a licensing agreement with Singapore-based Aeira to market and sell Kangyueda in 18 markets across Central and Southeast Asia, according to a Wednesday bourse filing.</p><p>Kangyueda is approved to treat moderate-to-severe atopic dermatitis in adults, chronic rhinosinusitis with nasal polyposis and seasonal allergic rhinitis, the filing said.</p><p>Under the deal, Keymed will receive an upfront payment, milestone payments upon hitting certain targets and royalties in the high-double-digit percentage range based on regional sales.</p><p>Aeira will be responsible for regulatory filings and the commercialization of Kangyueda in markets including Singapore, Malaysia, the Philippines, Thailand, Kazakhstan and Uzbekistan, as well as Hong Kong and Macau.</p><p>Keymed will oversee the production and timely supply of Kangyueda to Aeira.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2664582856","we_media_id":"1060499803","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2664582856","pubTimestamp":1788399758,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"MT Newswires","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1060499803","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Keymed Biosciences  has signed a licensing agreement with Singapore-based Aeira to market and sell Kangyueda in 18 markets across Central and Southeast Asia, according to a Wednesday bourse filing.Kangyueda is approved to treat moderate-to-severe atopic dermatitis in adults, chronic rhinosinusitis with nasal polyposis and seasonal allergic rhinitis, the filing said.Under the deal, Keymed will receive an upfront payment, milestone payments upon hitting certain targets and royalties in the high-double-digit percentage range based on regional sales.Aeira will be responsible for regulatory filings and the commercialization of Kangyueda in markets including Singapore, Malaysia, the Philippines, Thailand, Kazakhstan and Uzbekistan, as well as Hong Kong and Macau.Keymed will oversee the production and timely supply of Kangyueda to Aeira.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","BK1587":"次新股","BK1574":"生物医药B类股","BK1583":"高瓴概念","02162":"康诺亚-B"},"translate_title":"Keymed Biosciences 签署康悦达 18 个市场的许可协议","themeId":"b010cf239ffd4765bcd3edd8f767f746","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02162":0.9},"content_text":"Keymed Biosciences (HKG:2162) has signed a licensing agreement with Singapore-based Aeira to market and sell Kangyueda in 18 markets across Central and Southeast Asia, according to a Wednesday bourse filing.Kangyueda is approved to treat moderate-to-severe atopic dermatitis in adults, chronic rhinosinusitis with nasal polyposis and seasonal allergic rhinitis, the filing said.Under the deal, Keymed will receive an upfront payment, milestone payments upon hitting certain targets and royalties in the high-double-digit percentage range based on regional sales.Aeira will be responsible for regulatory filings and the commercialization of Kangyueda in markets including Singapore, Malaysia, the Philippines, Thailand, Kazakhstan and Uzbekistan, as well as Hong Kong and Macau.Keymed will oversee the production and timely supply of Kangyueda to Aeira.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.49.0","shortVersion":"4.49.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2664582856","isCrawlerRequest":true}